Format

Send to

Choose Destination
J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.

Author information

1
Sarah Cannon Research Institute, Nashville, Tennessee; Tennessee Oncology, PLLC, Nashville, Tennessee.
2
Gustave-Roussy Cancer Campus, Cancer Medicine Department, Villejuif, France; Paris-Sud University, Orday, France.
3
Vall d' Hebrón Institute of Oncology and University Hospital, Barcelona, Spain.
4
University Hospital Virgen de la Victoria, Málaga, Spain.
5
START Madrid-FJD, Jiménez Díaz Foundation Hospital, Madrid, Spain.
6
Ramón y Cajal University Hospital, IRYCIS, Alcalá University, Madrid, Spain.
7
GlaxoSmithKline, Collegeville, Pennsylvania.
8
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Electronic address: rgovindan@wustl.edu.

Abstract

INTRODUCTION:

This first-time-in-humans study assessed the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of GSK2879552 in patients with relapsed or refractory SCLC.

METHODS:

This phase I, multicenter, open-label study (NCT02034123) enrolled patients (≥18 years old) with relapsed or refractory SCLC (after ≥1 platinum-containing chemotherapy or refusal of standard therapy). Part 1 was a dose-escalation study; Part 2 was a dose-expansion study. Dose escalations were based on safety, PK, and PD. The primary end point (Part 1) was to determine the safety, tolerability, and recommended dose and regimen of GSK2879552. Secondary end points were to characterize PK and PD parameters and measure disease control rate at week 16. Part 2 was not conducted.

RESULTS:

Between February 4, 2014, and April 18, 2017, a total of 29 patients were allocated to one of nine dose cohorts (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing). In all, 22 patients completed the study; 7 withdrew, primarily owing to adverse events (AEs). Most patients (24 of 29 [83%]) had at least one treatment-related AE, most commonly thrombocytopenia (12 of 29 [41%]). Twelve serious AEs (SAEs) were reported by nine patients; six were considered treatment related, the most common of which was encephalopathy (four SAEs). Three patients died; one death was related to SAEs. PK was characterized by rapid absorption, slow elimination, and a dose-proportional increase in exposure.

CONCLUSIONS:

GSK2879552 is a potent, selective inhibitor of lysine demethylase 1A and has demonstrated favorable PK properties but provided poor disease control and a high AE rate in patients with SCLC. The study was terminated, as the risk-benefit profile did not favor continuation.

KEYWORDS:

GSK2879552; Pharmacodynamics; Pharmacokinetics; Safety; Small cell lung carcinoma

PMID:
31260835
DOI:
10.1016/j.jtho.2019.06.021
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center